HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Osamu Nagano Selected Research

Sulfasalazine (Azulfidine)

1/2020Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
11/2019Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
12/2018Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
9/2018Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.
11/2017Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).
9/2017Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
3/2017Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).
9/2016Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.
5/2016Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.
10/2013Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Osamu Nagano Research Topics

Disease

49Neoplasms (Cancer)
07/2022 - 06/2004
14Brain Neoplasms (Brain Tumor)
03/2020 - 01/2005
7Neoplasm Metastasis (Metastasis)
03/2022 - 02/2007
7Squamous Cell Carcinoma of Head and Neck
11/2019 - 02/2007
3Stomach Neoplasms (Stomach Cancer)
03/2022 - 03/2017
3Parkinson Disease (Parkinson's Disease)
01/2021 - 05/2012
3Breast Neoplasms (Breast Cancer)
03/2020 - 07/2008
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2020 - 01/2013
3Metaplasia
02/2017 - 10/2013
3Carcinogenesis
06/2015 - 03/2010
2Colorectal Neoplasms (Colorectal Cancer)
06/2022 - 09/2016
2Hypoxia (Hypoxemia)
03/2022 - 03/2012
2Leukoencephalopathies
09/2019 - 01/2017
2Glioma (Gliomas)
12/2018 - 01/2016
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
11/2017 - 09/2017
2Adenocarcinoma
02/2017 - 09/2016
2Leukemia
01/2017 - 12/2011
2Gastrointestinal Neoplasms (Gastrointestinal Cancer)
05/2014 - 03/2011
1Acoustic Neuroma (Acoustic Neurinoma)
01/2021
1Dyskinesias (Dyskinesia)
10/2019
1Astrocytoma (Pilocytic Astrocytoma)
10/2019
1Glioblastoma (Glioblastoma Multiforme)
10/2019
1Meningeal Neoplasms
09/2019
1Residual Neoplasm
06/2019
1Meningioma (Meningiomas)
06/2019
1Melanoma (Melanoma, Malignant)
01/2018
1Thyroid Neoplasms (Thyroid Cancer)
01/2018
1Pneumonia (Pneumonitis)
09/2017
1Hypotension (Low Blood Pressure)
09/2017
1Anorexia
09/2017

Drug/Important Bio-Agent (IBA)

10Sulfasalazine (Azulfidine)FDA LinkGeneric
01/2020 - 10/2013
10Glutathione (Reduced Glutathione)IBA
01/2020 - 01/2012
9Cystine (L-Cystine)IBA
11/2019 - 06/2012
7AntioxidantsIBA
01/2020 - 03/2012
7Glutamic Acid (Glutamate)FDA Link
11/2019 - 01/2016
7Reactive Oxygen Species (Oxygen Radicals)IBA
11/2017 - 03/2011
6Protein Isoforms (Isoforms)IBA
07/2022 - 06/2012
6Pharmaceutical PreparationsIBA
01/2020 - 06/2012
6Cisplatin (Platino)FDA LinkGeneric
10/2019 - 01/2016
5ErbB Receptors (EGF Receptor)IBA
12/2018 - 05/2008
3Glucose (Dextrose)FDA LinkGeneric
06/2022 - 03/2012
3LigandsIBA
10/2019 - 10/2017
3MicellesIBA
10/2019 - 01/2016
3Phosphotransferases (Kinase)IBA
12/2018 - 05/2008
3Small Interfering RNA (siRNA)IBA
12/2018 - 07/2008
32,5-dichloro-4-bromophenol (B 2)IBA
12/2018 - 12/2010
3spasmolytic polypeptideIBA
02/2017 - 10/2013
3Hyaluronic Acid (Hyaluronan)IBA
01/2017 - 12/2004
2Facilitative Glucose Transport Proteins (Glucose Transporter)IBA
06/2022 - 10/2019
2EnzymesIBA
03/2022 - 01/2020
2Mitogen-Activated Protein KinasesIBA
03/2022 - 09/2011
2Biomarkers (Surrogate Marker)IBA
01/2020 - 11/2019
2IronIBA
01/2020 - 09/2018
2Biological ProductsIBA
12/2019 - 12/2016
2Amino AcidsFDA Link
11/2019 - 01/2016
2AntiportersIBA
11/2019 - 09/2018
2PlatinumIBA
07/2017 - 01/2016
2Epithelial Cell Adhesion MoleculeIBA
07/2017 - 11/2011
2Cadherins (E-Cadherin)IBA
09/2016 - 07/2008
2Monoclonal AntibodiesIBA
01/2016 - 05/2008
2tyrosine receptor (receptor, tyrosine)IBA
01/2016 - 05/2008
2ADAM17 ProteinIBA
01/2008 - 02/2007
1AngiopoietinsIBA
06/2022
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2022
1trametinibIBA
03/2022
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
03/2022
1Prostaglandin-E SynthasesIBA
03/2022
1Hormones (Hormone)IBA
03/2020
1Vasodilator Agents (Vasodilators)IBA
01/2020
1Lipid PeroxidesIBA
01/2020
1Aldehyde DehydrogenaseIBA
01/2020
14-hydroxy-2-nonenal (4-hydroxynonenal)IBA
01/2020
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2020
1OxyfedrineIBA
01/2020
1AldehydesIBA
01/2020
1Membrane Transport Proteins (Biological Pump)IBA
11/2019
1Glutamine (L-Glutamine)FDA Link
11/2019
1Epidermal Growth Factor (EGF)IBA
12/2018
1N-Methylaspartate (NMDA)IBA
12/2018
1Dizocilpine Maleate (Dizocilpine)IBA
12/2018
1Glutamate Receptors (Glutamate Receptor)IBA
12/2018
1dyclonine (Sucrets)FDA Link
09/2018
1TaurineFDA Link
01/2018
1GoldIBA
01/2018
1hypotaurineIBA
01/2018
1cyclic arginine-glycine-aspartic acid peptideIBA
10/2017
1IntegrinsIBA
10/2017
1arginyl-glycyl-aspartic acidIBA
10/2017
1Alanine Transaminase (SGPT)IBA
09/2017

Therapy/Procedure

15Radiotherapy
03/2020 - 12/2006
10Therapeutics
01/2020 - 03/2013
6Drug Therapy (Chemotherapy)
09/2017 - 12/2011
3Transplantation
03/2022 - 06/2012
3Deep Brain Stimulation
01/2021 - 05/2012
2Aftercare (After-Treatment)
01/2016 - 06/2015
2Activities of Daily Living (ADL)
12/2010 - 12/2006
1Conservative Treatment
01/2021
1Lasers (Laser)
10/2019
1Combined Modality Therapy
06/2019
1Immunotherapy
01/2018